Detalhe da pesquisa
1.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38507751
2.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med
; 386(12): 1143-1154, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320644
3.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665782
4.
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
Drug Resist Updat
; 75: 101086, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38677200
5.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495879
6.
Adjuvant treatment strategy evolution and risk stratification for hormone receptor-positive, human epidermal growth factor receptor-2 negative early breast cancer in China.
Oncologist
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38780143
7.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Oncologist
; 29(4): e514-e525, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38297981
8.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Future Oncol
; 20(8): 423-436, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37387213
9.
A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer.
Chin J Cancer Res
; 36(1): 46-54, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38455366
10.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(6): 646-657, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182538
11.
The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status.
Int J Cancer
; 153(7): 1324-1336, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37314204
12.
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
Int J Cancer
; 153(4): 803-814, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36971103
13.
Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.
Int J Cancer
; 153(10): 1809-1818, 2023 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543965
14.
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.
Int J Cancer
; 152(10): 2134-2144, 2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36621000
15.
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Oncologist
; 28(12): e1259-e1267, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37338150
16.
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
Breast Cancer Res Treat
; 197(3): 503-513, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36463547
17.
Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up.
Breast Cancer Res Treat
; 197(3): 569-582, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36469156
18.
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Breast Cancer Res Treat
; 197(3): 489-501, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36459284
19.
Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors.
Invest New Drugs
; 41(3): 503-511, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171721
20.
Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors.
BMC Cancer
; 23(1): 1200, 2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38057772